{"id":"ro-actemra","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Infection (including serious infections)"},{"rate":"10-15","effect":"Elevated liver enzymes"},{"rate":"10-15","effect":"Hyperlipidemia"},{"rate":"5-10","effect":"Neutropenia"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Hypertension"}]},"_chembl":{"chemblId":"CHEMBL4303496","moleculeType":"Small molecule","molecularWeight":"319.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tocilizumab binds to both soluble and membrane-bound IL-6 receptors, inhibiting IL-6-mediated signal transduction. This suppresses the production of inflammatory cytokines and acute phase reactants, reducing systemic inflammation in autoimmune and inflammatory conditions.","oneSentence":"Ro-Actemra (tocilizumab) is an IL-6 receptor antagonist that blocks interleukin-6 signaling to reduce inflammatory responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:15.836Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Giant cell arteritis"},{"name":"Polyarticular juvenile idiopathic arthritis"},{"name":"Systemic sclerosis-associated interstitial lung disease"},{"name":"COVID-19 (severe or critical)"}]},"trialDetails":[{"nctId":"NCT04729959","phase":"PHASE2","title":"Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-11","conditions":"Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma","enrollment":59},{"nctId":"NCT01638715","phase":"PHASE4","title":"A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2012-05","conditions":"Rheumatoid Arthritis","enrollment":115},{"nctId":"NCT02837146","phase":"PHASE3","title":"Ultrasound as Imaging Biomarker of Early Response to Tocilizumab and Methotrexate in Very Early Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Maria Stoenoiu","startDate":"2015-12","conditions":"Rheumatoid Arthritis","enrollment":45},{"nctId":"NCT01727206","phase":"PHASE2","title":"Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease","status":"TERMINATED","sponsor":"Ospedale San Raffaele","startDate":"2012-11","conditions":"Erdheim-Chester Disease","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ro-Actemra","genericName":"Ro-Actemra","companyName":"Medical University of Vienna","companyId":"medical-university-of-vienna","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ro-Actemra is a small molecule used in the treatment of various conditions, including Rheumatoid Arthritis, Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma, and Erdheim-Chester Disease. It has been studied in combination with other interventions, such as Remicade and Orencia, in clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}